New Data from VISION VE on mRNA Vaccines in Sustaining or Improving Protection Against COVID-19

New research underscores the importance of a 3rd dose mRNA vaccine against COVID-19 and reinforces importance of considering additional doses to sustain or improve protection against the disease. The Centers for Disease Control and Prevention’s (CDC’s) VISION VE project, which this data comes from, continues to provide real-time data for decisionmaking in moving through the pandemic.

The data have been published in the CDC’s Morbidity and Mortality Weekly Report (MMWR): Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022. Coauthors include Westat’s Patrick K. Mitchell, Sc.D., Sarah E. Reese, Ph.D., Duck-Hye Yang, Ph.D., and Rebecca Birch, MPH.

The VISION VE project integrates medical, laboratory, pharmacy, and vaccination records to examine incidence, care trajectories, and outcomes associated with COVID-19 illness.